Phase 3 Study of Efficacy and Safety of the XaraColl® Bupivacaine Implant After Hernioplasty
Public ClinicalTrials.gov record NCT02523599. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of the XaraColl® Bupivacaine Implant (300 mg Bupivacaine Hydrochloride) After Open Laparotomy Hernioplasty
Study identification
- NCT ID
- NCT02523599
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Innocoll
- Industry
- Enrollment
- 305 participants
Conditions and interventions
Conditions
Interventions
- XaraColl Drug
- Placebo Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2015
- Primary completion
- Mar 31, 2016
- Completion
- Mar 31, 2016
- Last update posted
- Jan 7, 2021
2015 – 2016
United States locations
- U.S. sites
- 23
- U.S. states
- 10
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Mobile | Alabama | 36617 | — |
| Not listed | Sheffield | Alabama | 35660 | — |
| Not listed | Phoenix | Arizona | 85023 | — |
| Not listed | Little Rock | Arkansas | 72205 | — |
| Not listed | Encino | California | 91436 | — |
| Not listed | Bradenton | Florida | 34206 | — |
| Not listed | Clermont | Florida | 34711 | — |
| Not listed | Inverness | Florida | 34452 | — |
| Not listed | Kissimmee | Florida | 34741 | — |
| Not listed | Miami | Florida | 33136 | — |
| Not listed | Miami | Florida | 33144 | — |
| Not listed | Orlando | Florida | 32825 | — |
| Not listed | St. Petersburg | Florida | 33713 | — |
| Not listed | Tampa | Florida | 33606 | — |
| Not listed | Weston | Florida | 33331 | — |
| Not listed | Indianapolis | Indiana | 46202 | — |
| Not listed | Springfield | Massachusetts | 01199 | — |
| Not listed | Flint | Michigan | 48532 | — |
| Not listed | Las Vegas | Nevada | 89102 | — |
| Not listed | Las Vegas | Nevada | 89106 | — |
| Not listed | El Paso | Texas | 79935 | — |
| Not listed | Houston | Texas | 77054 | — |
| Not listed | Lampasas | Texas | 76550 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02523599, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 7, 2021 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02523599 live on ClinicalTrials.gov.